Medipure News

THE ENDOCANNABINOID SYSTEM A PHYSICIANS PERSPECTIVE

Most physicians are constantly learning not only for their benefit but, more importantly, for the benefit of their patients.  It is not surprising therefore that there is considerable interest in the endocannabinoid system (ECS) as this system has only been recently recognized and appreciated.  I think it is fair to say that over the last decade there has been more interest in the ECS than any other system in our body and understanding this system has generated an awareness of therapeutic potentials in many health-related areas.

COVID -19… A Physicians Perspective

September 2020

I am writing this as Medical Director of Medipure Pharmaceuticals to provide some of my own perspective to this very unique period in our history.

The WHO declared Covid-19 as a worldwide viral pandemic on March 11, 2020 and in our province (British Columbia) a province wide “state of emergency” was instituted a week later on March 18.

Coronavirus disease is a novel infectious disease caused by severe acute respiratory syndrome coronavirus 2.  This virus is in the same family as the virus that caused the significant SARS outbreak in 2002-2004.

Medipure Holdings Inc. Announces Publication of U.S. and International PCT Patent Application for MP20X, a Drug Formulation to Treat Anxiety and Depression

Vancouver, BC – September # 2020 – Medipure Holdings Inc. (“Medipure” or the “Company”), is pleased to announce the publication of U.S. patent applications 20200253947 and 20200253948 and the publication international PCT patent application (PCT/CA2020/050165) for MP20X. The published patents relate to pharmaceutical formulations for treating anxiety and depression, specifically, formulations that combine one or more than one cannabinoid receptor agonist and one or more than one serine hydrolase enzyme inhibitor as anxiolytic therapeutic product.

 

MEDIPURE ANNOUNCES KEY ADDITION TO CORPORATE TEAM

Vancouver, BC –May, 2019 - Medipure Holdings. Inc., parent company of Medipure Pharmaceuticals Inc., a biopharmaceutical incubator committed to discovering and developing proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms, today announced the appointment of Rman Walia, CPA, CA as its Corporate Controller.

MEDIPURE ANNOUNCES KEY ADDITION TO TAKE COMPANY TO NEXT STAGE OF DEVELOPMENT

Vancouver, BC – February, 2019 - Medipure Holdings Inc., a biopharmaceutical incubator committed to discovering and developing proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms, today announced the appointment of Alan C. Mendelson as Corporate Secretary and Advisor to the Board of Directors.

MEDIPURE ANNOUNCES APPOINTMENT OF RENOWNED CROATIAN HEALTH SPECIALIST

Vancouver, BC – February,  2019 - Medipure Holdings Inc., a biopharmaceutical incubator committed to discovering and developing proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms, today announced the appointment of Dr. Ognjen Brborović to its Scientific Advisory Board.

MEDIPURE ANNOUNCES KEY APPOINTMENT TO CROATIA SUBSIDIARY

Vancouver, BC – February, 2019 - Medipure Holdings Inc., a biopharmaceutical incubator committed to discovering and developing proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms, today announced the appointment of Dr. Miroslav Weiss as Medical Director of its subsidiary in Croatia.

MEDIPURE ANNOUNCES DIRECTOR OF OPERATIONS FOR CROATIAN SUBSIDIARY

Vancouver, BC – October 29, 2018: Medipure Pharmaceuticals Inc., a biopharmaceutical incubator committed to discovering and developing proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms, today announced the appointment of Dr. Dubravko Kičić as Director of Operations for its Croatian subsidiary.

Pages

more